$\require{mediawiki-texvc}$

연합인증

연합인증 가입 기관의 연구자들은 소속기관의 인증정보(ID와 암호)를 이용해 다른 대학, 연구기관, 서비스 공급자의 다양한 온라인 자원과 연구 데이터를 이용할 수 있습니다.

이는 여행자가 자국에서 발행 받은 여권으로 세계 각국을 자유롭게 여행할 수 있는 것과 같습니다.

연합인증으로 이용이 가능한 서비스는 NTIS, DataON, Edison, Kafe, Webinar 등이 있습니다.

한번의 인증절차만으로 연합인증 가입 서비스에 추가 로그인 없이 이용이 가능합니다.

다만, 연합인증을 위해서는 최초 1회만 인증 절차가 필요합니다. (회원이 아닐 경우 회원 가입이 필요합니다.)

연합인증 절차는 다음과 같습니다.

최초이용시에는
ScienceON에 로그인 → 연합인증 서비스 접속 → 로그인 (본인 확인 또는 회원가입) → 서비스 이용

그 이후에는
ScienceON 로그인 → 연합인증 서비스 접속 → 서비스 이용

연합인증을 활용하시면 KISTI가 제공하는 다양한 서비스를 편리하게 이용하실 수 있습니다.

Antibody-therapeutic agent conjugates 원문보기

IPC분류정보
국가/구분 United States(US) Patent 등록
국제특허분류(IPC7판)
  • A61K-039/00
  • A61K-037/00
  • A23J-037/00
출원번호 US-0650375 (1984-09-13)
발명자 / 주소
  • Goers John W. F. (Atascadero CA) King Hurley D. (Yardley PA) Lee Chyi (New Brunswick NJ) Coughlin Daniel J. (Plainsboro NJ) Alvarez Vernon L. (Morrisville PA) Rodwell John D. (Yardley PA) McKearn Tho
출원인 / 주소
  • Cytogen Corporation (Princeton NJ 02)
인용정보 피인용 횟수 : 189  인용 특허 : 9

초록

This invention relates to antibody-therapeutic agent conjugates having a therapeutic agent covalently attached to an antibody or antibody fragment. Also described are methods for intermediates in the preparation of antibody conjugates. Therapeutic in vivo methods utilizing such antibody-therapeutic

대표청구항

A method for preparing a pharmaceutical antibody-therapeutic agent conjugate composition suitable for in vivo administration and for the in vivo delivery of a therapeutic agent, comprising: (a) reacting an antibody or antibody fragment with an oxidizing agent to form an aldehyde group in a carbohydr

이 특허에 인용된 특허 (9)

  1. Rodwell John D. (Yardley PA) McKearn Thomas J. (Narberth PA), Antibody conjugates for the delivery of compounds to target sites.
  2. Gargiulo Robert J. (Miami FL) Driscoll Richard C. (Lake Forest IL), Composition and method for determining transferase and protease activity.
  3. Ali Majid (19 Edgemont Pl. Teaneck NJ 07666) Nalebuft Donald (89 Lake Shore Dr. Oakland NJ 07436) Fayemi Alfred (15 Francine Ct. White Plains NY 10607) Ramanarayanan Madhava P. (100 Haven Ave. New Yo, Enzyme immunoassay for allergic disorders.
  4. Zaborsky Oskar R. (Watchung NJ) Laskin Allen I. (New York NY), Immobilized glycoenzymes.
  5. Sela ; Michael ; Arnon ; Ruth ; Maron ; Ruth ; Hurvitz ; Esther, Immunologic chemotherapeutic agents comprising antigen binding dimers covalently bound to drugs.
  6. Quash Gerard A. (Sainte Foy Les Lyon FRX), Novel supports carrying side chains, processes for obtaining these supports, process for attaching organic compounds hav.
  7. Quash Gerard A. (Sainte Foy les Lyon FRX), Novel supports carrying side chains, processes for obtaining these supports, process for attaching organic compounds hav.
  8. Sela Michael (Rehovot ILX) Arnon Ruth (Rehovot ILX) Hurvitz Esther (Rehovot ILX) Maron Ruth (Tel Aviv ILX) Levy Ron (Rehovot ILX), Pharmaceutically active compositions containing adriamycin and daunomycin.
  9. Kotani Kikuo (Shizuoka JPX) Ohyama Kunio (Shizuoka JPX) Nakagawa Nobuaki (Shizuoka JPX) Fujii Tadashiro (Mishima JPX) Watanabe Susumu (Shizuoka JPX), Polyfunctional disulfide compounds having S-S exchange reactivity.

이 특허를 인용한 특허 (189)

  1. Ting, Angela H.; Lee, Byron H., ABCA1 downregulation in prostate cancer.
  2. Daugherty, Patrick Sean; Stagliano, Nancy; Thomas, Jerry; Kamath, Kathryn; West, James W.; Khare, Sanjay; Sagert, Jason, Activatable binding polypeptides and methods of identification and use thereof.
  3. Daugherty, Patrick Sean; Stagliano, Nancy; Thomas, Jerry; Kamath, Kathryn; West, James W.; Khare, Sanjay; Sagert, Jason, Activatable binding polypeptides and methods of identification and use thereof.
  4. Daugherty, Patrick Sean; Stagliano, Nancy; Thomas, Jerry; Kamath, Kathryn; West, James W.; Khare, Sanjay; Sagert, Jason, Activatable binding polypeptides and methods of identification and use thereof.
  5. Daugherty, Patrick Sean; Stagliano, Nancy; Thomas, Jerry; West, James W.; Sagert, Jason, Activatable binding polypeptides and methods of identification and use thereof.
  6. Daugherty, Patrick; Stagliano, Nancy; Thomas, Jerry; Kamath, Kathryn; West, James W.; Khare, Sanjay; Sagert, Jason, Activatable binding polypeptides and methods of identification and use thereof.
  7. Ogura, Kyoichi; Iino, Taeko; Asami, Sumio, Angiotensin-converting enzyme inhibitory peptides.
  8. Teirstein, Paul S.; Carpenter, Kenneth W.; Szinai, Istvan; Schwartz, David A., Animal model for detection of vulnerable plaques.
  9. Ruiz-Opazo, Nelson; Herrera, Victoria L. M., Anti-DEspR inhibitors as therapeutics for inhibition of pathological angiogenesis and tumor cell invasiveness and for molecular imaging and targeted delivery.
  10. Ruiz-Opazo, Nelson; Herrera, Victoria L. M.; Carr, Francis Joseph, Anti-DEspR monoclonal antibody targeted therapy and imaging for cancer and stroke.
  11. Stagliano, Nancy Elizabeth; West, James William; Kamath, Kathryn; Bessette, Paul Henry; Gluck, Fred; Sagert, Jason Gary; Daugherty, Patrick, Anti-EGFR activatable antibodies.
  12. King C. Richter (Washington DC) Kasprzyk Philip G. (Washington DC) Bird Robert E. (Rockville MD), Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof.
  13. Brown, Eric J.; Darwish, Martine; Flygare, John; Hazenbos, Wouter; Lee, Byoung Chul; Lehar, Sophie M.; Mariathasan, Sanjeev; Morisaki, John Hiroshi; Pillow, Thomas H.; Staben, Leanna; Vandlen, Richard; Koefoed, Klaus; Strandh, Magnus; Andersen, Peter S., Anti-wall teichoic antibodies and conjugates.
  14. Brown, Eric J.; Flygare, John; Hazenbos, Wouter; Lehar, Sophie M.; Mariathasan, Sanjeev; Morisaki, John Hiroshi; Pillow, Thomas H.; Staben, Leanna; Vandlen, Richard; Koefoed, Klaus; Strandh, Magnus; Andersen, Peter S., Anti-wall teichoic antibodies and conjugates.
  15. Brown, Eric J.; Flygare, John; Hazenbos, Wouter; Lehar, Sophie M.; Mariathasan, Sanjeev; Morisaki, John Hiroshi; Pillow, Thomas H.; Staben, Leanna; Vandlen, Richard; Koefoed, Klaus; Strandh, Magnus; Andersen, Peter S., Anti-wall teichoic antibodies and conjugates.
  16. Kim, Stanley A., Antibiotic-conjugated antibodies.
  17. Hostetler Karl Y., Antiviral liponucleosides: treatment of hepatitis B.
  18. Virtanen Jorma ; Virtanen Sinikka, Antiviral liposome having coupled target-binding moiety and hydrolytic enzyme.
  19. Virtanen Jorma ; Virtanen Sinikka, Antiviral supramolecules containing target-binding molecules and therapeutic molecules bound to spectrin.
  20. Morales Guillermo ; Li Weixing ; Jackson Paul F., Asymmetric syntheses and intermediates for preparing enantiomer-enriched hydroxyphosphinyl derivatives.
  21. King Dalton ; Firestone Raymond A. ; Trail Pamela, Branched hydrazone linkers.
  22. Mark J. Evans ; Louis A. Matis ; Eileen Elliott Mueller ; Steven H. Nye ; Scott Rollins ; Russell P. Rother ; Jeremy P. Springhorn ; Stephen P. Squinto ; Thomas C. Thomas ; James A. Wilkins, C5-specific antibodies for the treatment of inflammatory diseases.
  23. Bayley Hagen ; Walker Barbara J., Cell-targeted lytic pore-forming agents.
  24. Bayley Hagen ; Walker Barbara J., Cell-targeted lytic pore-forming agents.
  25. Celis, Esteban, Chimeric antigen-specific T cell-activating polypeptides.
  26. Celis, Esteban, Chimeric antigen-specific t cell-activating polypeptides.
  27. Koppel Gary A. (Indianapolis IN) Offord Robin E. (Collex-Bossy CHX) Rose Keith (Geneva IN CHX) Scott William L. (Indianapolis IN), Cluster conjugates of drugs with antibodies.
  28. Mezes Peter S. ; Richard Ruth A. ; Johnson Kimberly S., Composite antibodies of human subgroup IV light chain capable of binding to tag-72.
  29. Rouau, Xavier; Schrøder, Mette; Søe, Jørn Borch, Composition comprising an enzyme having galactose oxidase activity and use thereof.
  30. Waldman, Scott A.; Park, Jason; Schulz, Stephanie, Compositions and methods for identifying and targeting cancer cells of alimentary canal origin.
  31. Waldman, Scott A.; Park, Jason; Schulz, Stephanie, Compositions and methods for identifying and targeting cancer cells of alimentary canal origin.
  32. Waldman, Scott A.; Park, Jason; Schulz, Stephanie, Compositions and methods for identifying and targeting cancer cells of alimentary canal origin.
  33. Waldman, Scott A.; Park, Jason; Schulz, Stephanie, Compositions and methods for identifying and targeting cancer cells of alimentary canal origin.
  34. Hubbell, Jeffrey A.; Kontos, Stephan; Dane, Karen Y., Compositions for generating immune tolerance by targeting erythrocytes.
  35. Hubbell, Jeffrey A.; Kontos, Stephan; Dane, Karen Y., Compositions for inducing antigen-specific tolerance.
  36. Jones Dean P. ; Furukawa Satoru,JPX, Compounds and their combinations for the treatment of influenza infection.
  37. Jones Dean P. ; Furukawa Satoru,JPX, Compounds and their combinations for the treatment of influenza infection.
  38. Shekhani Mohammed Saleh ; Firca Joseph R. ; Anderson Byron, Compounds that bind bacterial pili.
  39. Kopia Gregory A. (Phoenixville PA) Horan Paul K. (Downingtown PA) Gray Brian D. (Ardmore PA) Troutner David E. (Phoenixville PA) Muirhead Katharine A. (West Chester PA) Sheth Kamleshkumar A. (Downing, Compounds, compositions and methods for binding bio-affecting substances to surface membranes of bio-particles.
  40. Chang Tse Wen, Conjugates of microbeads and antibodies specific for T lymphocytes and their use as in vivo immune modulators.
  41. Combs, Rodney G.; Roe, Susanna; Ruble, Derrick L., Control of RAGE fusion protein glycosylation and RAGE fusion protein compositions.
  42. Young,David S. F.; Findlay,Helen P.; Hahn,Susan E.; da Cruz,Luis A. G.; Sayegh,Daad; Rogers,Kristian; Kumar,Shankar; Hinton,Paul, Cytotoxicity mediation of cells evidencing surface expression of CD63.
  43. Bayley, Hagan; Braha, Orit; Kasianowicz, John; Gouaux, Eric, Designed protein pores as components for biosensors.
  44. Goldenberg M. David, Detection and treatment of infections with immunoconjugates.
  45. Goldenberg, M. David, Detection and treatment of infections with immunoconjugates.
  46. Awwad Michel G. ; Abraham Sonny ; White-Scharf Mary E. ; Hope James A., Determination of antibody production against administered therapeutic glycoproteins, especially monoclonal antibodies.
  47. Potter, Andrew A.; Redmond, Mark J.; Hughes, Huw P. A., Enhanced immunogenicity using leukotoxin chimeras.
  48. Hubbell, Jeffrey A.; Kontos, Stéphane; Dane, Karen Y., Erythrocyte-binding therapeutics.
  49. Majeti, Ravindra; Weissman, Irving L., Ex vivo methods for targeting or depleting acute myeloid leukemia cancer stem cells.
  50. Mezes Peter S. ; Gourlie Brian B. ; Rixon Mark W. ; Schlom Jeffrey ; Kaplan Donald A. ; Anderson W. H. Kerr, Family of high affinity, modified antibodies for cancer treatment.
  51. Goldor, Ori; Rotem, Shachar, Finger-type peristaltic pump.
  52. Hubbell, Jeffrey A.; Wilson, David Scott, Glycotargeting therapeutics.
  53. Strome, Scott E.; Celis, Esteban, HPV 16 peptide vaccine for head and neck cancer.
  54. Vistica, Cynthia A.; Holmes, Eric H.; Brams, Peter; Witte, Alison; Cardarelli, Josephine M., Human monoclonal antibodies to Fucosyl-GM1 and methods for using anti-Fucosyl-GM1 antibodies.
  55. Vistica, Cynthia A.; Holmes, Eric H.; Brams, Peter; Witte, Alison; Cardarelli, Josephine M., Human monoclonal antibodies to fucosyl-GM1 and methods for using anti-fucosyl-GM1.
  56. Vistica, Cynthia A.; Holmes, Eric H.; Brams, Peter; Witte, Alison; Cardarelli, Josephine M., Human monoclonal antibodies to fucosyl-GM1 and methods for using anti-fucosyl-GM1 antibodies.
  57. Hoon, David S. B., Human tumor-associated gene.
  58. Liu, Jie; Weissman, Irving L.; Majeti, Ravindra, Humanized and chimeric monoclonal antibodies to CD47.
  59. Liu, Jie; Weissman, Irving L.; Majeti, Ravindra, Humanized and chimeric monoclonal antibodies to CD47.
  60. Queen Cary L. (Los Altos CA) Co Man Sung (Cupertino CA) Schneider William P. (Mountain View CA) Landolfi Nicholas F. (Milpitas CA) Coelingh Kathleen L. (San Francisco CA) Selick Harold E. (Belmont CA, Humanized immunoglobulins.
  61. Queen Cary L. (Los Altos CA) Selick Harold E. (Belmont CA), Humanized immunoglobulins.
  62. Queen,Cary L.; Selick,Harold E., Humanized immunoglobulins.
  63. Queen Cary L. ; Selick Harold E., Humanized immunoglobulins and methods of making the same.
  64. Jackson Paul F. ; Tays Kevin L. ; MacLin Keith M. ; Slusher Barbara S., Hydroxamic acid derivatives.
  65. Jackson Paul F. ; Tays Kevin L. ; Maclin Keith M. ; Slusher Barbara S., Hydroxamic acid derivatives.
  66. Bucala Richard J. (New York NY), Immunochemical detection of In vivo advanced glycosylation end products.
  67. Mezo, Adam R.; McDonnell, Kevin A., Immunomodulatory peptides.
  68. Mather, Jennie P.; Loo, Deryk T., KID31 and antibodies that bind thereto.
  69. Mather, Jennie P.; Loo, Deryk T., KID31 and antibodies that bind thereto.
  70. Basava Channa ; Hostetler Karl Y., Lipid conjugates of therapeutic peptides and protease inhibitors.
  71. Hostetler Karl Y. ; Kumar Raj ; Sridhar Nagarajan C., Lipid prodrugs for oral administration.
  72. Firestone Raymond Armand ; Dubowchik Gene Michael, Lysosomal enzyme-cleavable antitumor drug conjugates.
  73. Majeti, Ravindra; Weissman, Irving L., Markers of acute myeloid leukemia stem cells.
  74. Majeti, Ravindra; Weissman, Irving L., Markers of acute myeloid leukemia stem cells.
  75. Majeti, Ravindra; Weissman, Irving L., Markers of acute myeloid leukemia stem cells.
  76. Dees, H. Craig; Scott, Timothy C., Medicaments for chemotherapeutic treatment of disease.
  77. Scott, Timothy C.; Dees, H. Craig; Wachter, Eric A., Medicaments for chemotherapeutic treatment of disease.
  78. Jackson Paul F. ; Slusher Barbara S., Metabotropic glutamate receptor ligand derivatives as naaladase inhibitors.
  79. Deger Arno,DEX ; Guillot Fran.cedilla.ois,FRX ; Berger Michael,DEX ; Schlieper Dittmar,DEX, Method for carrying out a homogeneous-immunoassay based on agglutination.
  80. Weinberg Andrew D., Method for enhancing an antigen specific immune response with OX-40L.
  81. Adair, Charles David, Method for extending pregnancy by reducing intraventricular hemorrhaging in patients exhibiting at least one symptom of preeclampsia and eclampsia.
  82. Ragheb,Anthony O.; Fearnot,Neal E.; Voorhees, III,William D.; Kozma,Thomas G.; Bates,Brian L.; Osborne,Thomas A., Method of treating a patient with a coated implantable medical device.
  83. Goldstein, Richard N., Methods and compositions for designing vaccines.
  84. Goldstein, Richard N., Methods and compositions for determining species of bacteria and fungi.
  85. Weinberg,Andrew D., Methods for enhancing antigen-specific immune response using antibodies that bind OX-40.
  86. Hubbell, Jeffrey A.; Kontos, Stephan; Dane, Karen Y., Methods for induction of antigen-specific immune tolerance.
  87. Reiter, Robert E; Witte, Owen N, Methods for inhibiting the growth of cancer cells expressing PSCA.
  88. Jaiswal, Siddhartha; Weissman, Irving L.; Majeti, Ravindra; Chao, Mark P., Methods for manipulating phagocytosis mediated by CD47.
  89. Jaiswal, Siddhartha; Weissman, Irving L.; Majeti, Ravindra; Chao, Mark P., Methods for manipulating phagocytosis mediated by CD47.
  90. Jaiswal, Siddhartha; Weissman, Irving L.; Majeti, Ravindra; Chao, Mark P., Methods for manipulating phagocytosis mediated by CD47.
  91. Hubbell, Jeffrey A.; Kontos, Stephan; Dane, Karen Y., Methods for reducing immune responses.
  92. Barbara S. Slusher ; Xi-Chun May Lu ; Krystyna Wozniak, Methods for treating certain diseases using naaladase inhibitors.
  93. Slusher, Barbara S.; Lu, Xi-Chun May; Wozniak, Krystyna, Methods for treating certain diseases using naaladase inhibitors.
  94. Weinberg, Andrew D., Methods for using OX-40 ligand to enhance an antigen specific immune response.
  95. Barbara S. Slusher ; Paul F. Jackson ; Kevin L. Tays ; Keith M. Maclin, Methods of cancer treatment using NAALADase inhibitors.
  96. Slusher Barbara S. ; Jackson Paul F. ; Tays Kevin L. ; Maclin Keith M., Methods of cancer treatment using naaladase inhibitors.
  97. Kraus Matthias H. ; Aaronson Stuart A., Methods of characterizing ligands for the erbB-3 receptor, methods of influencing erbB-3 activities and methods of diag.
  98. Jaiswal, Siddhartha; Weissman, Irving L.; Majeti, Ravindra; Chao, Mark P., Methods of manipulating phagocytosis mediated by CD47.
  99. Jaiswal, Siddhartha; Weissman, Irving L.; Majeti, Ravindra; Chao, Mark P., Methods of manipulating phagocytosis mediated by CD47.
  100. Jaiswal, Siddhartha; Weissman, Irving L.; Majeti, Ravindra; Chao, Mark P., Methods of manipulating phagocytosis mediated by CD47.
  101. Waldman, Scott A.; Park, Jason; Schulz, Stephanie, Methods of screening and diagnosing esophageal cancer by determining guanylin cyclase C expression.
  102. Jaiswal, Siddhartha; Weissman, Irving L.; Majeti, Ravindra; Chao, Mark P., Methods of treating acute myeloid leukemia by blocking CD47.
  103. Waldman Scott A., Methods of treating metastatic colorectal cancer with ST receptor binding compounds.
  104. Hostetler, Karl Y.; Kumar, Raj; Stuhmiller, Louise M., Methods of treating viral infections using antiviral liponucleotides.
  105. Orme, Jacob, Methods of using ideotypically modulated pharmacoeffectors for selective cell treatment.
  106. Stagliano, Nancy E.; West, James W.; Kamath, Kathryn; Bessette, Paul H.; Gluck, Fred; Sagert, Jason; Daugherty, Patrick, Modified antibody compositions, methods of making and using thereof.
  107. Stagliano, Nancy E.; West, James W.; Kamath, Kathryn; Bessette, Paul H.; Gluck, Fred; Sagert, Jason; Daugherty, Patrick, Modified antibody compositions, methods of making and using thereof.
  108. Stagliano, Nancy E.; West, James W.; Kamath, Kathryn; Bessette, Paul H.; Gluck, Frederick W.; Sagert, Jason; Daugherty, Patrick, Modified antibody compositions, methods of making and using thereof.
  109. Stagliano, Nancy E.; West, James William; Kamath, Kathryn; Bessette, Paul Henry; Gluck, Fred; Sagert, Jason Gary; Daugherty, Patrick, Modified antibody containing the cleavable peptide with the amino acid sequence TGRGPSWV.
  110. Chang Tse Wen, Modified binding molecules specific for T lymphocytes and their use as in vivo immune modulators in animals.
  111. Chang Tse Wen, Modified binding molecules specific for T or B lymphocytes and their use as in vivo immune modulators.
  112. Johns, Terrance Grant; Stockert, Elizabeth; Old, Lloyd J.; Scott, Andrew M.; Rayzman, Veronika M., Monoclonal antibody 175 targeting the EGF receptor and derivatives and uses thereof.
  113. Reiter,Robert E.; Witte,Owen N., Mouse prostate stem cell antigen and uses thereof.
  114. Paul F. Jackson ; Keith M. Maclin ; Eric Wang ; Barbara S. Slusher ; Rena S. Lapidus ; Pavel Majer, NAALADase inhibitors useful as pharmaceutical compounds and compositions.
  115. Nitecki, Danute E.; Moreland, Margaret, Novel cross-linking agents.
  116. Mjalli, Adnan M. M.; Rothlein, Robert; Tian, Ye Edward; Webster, Jeffrey C., Nucleic acid molecules encoding rage fusion proteins.
  117. Avila, Luis Z.; Pan, Clark Q.; Finn, Patrick; Harrahy, John; Zhou, Qun; Zhu, Yunxiang; Konowicz, Paul A.; Paterson, Duncan E.; Peer, Andreas; Kutzko, Joseph P.; Reardon, Michael R.; Stefano, James E.; Zheng, Xiaoyang; Miller, Robert J.; Young, Lauren, Oligosaccharide-protein conjugates.
  118. Avila, Luis Z.; Pan, Clark Q.; Finn, Patrick; Harrahy, John; Zhou, Qun; Zhu, Yunxiang; Konowicz, Paul A.; Paterson, Duncan E.; Peer, Andreas; Kutzko, Joseph P.; Reardon, Michael R.; Stefano, James E.; Zheng, Xiaoyang; Miller, Robert J.; Young, Lauren, Oligosaccharide-protein conjugates.
  119. Sherman,Linda A.; Card,Kimberlyn F.; Weidanz,Jon A.; Wong,Hing C.; Thomson,Elizabeth L., P53 binding T cell receptor molecules.
  120. Reiter, Robert E.; Witte, Owen N., PSCA: prostate stem cell antigen and distinguishing androgen receptor negative prostate cancer from benign prostatic hyperplasia.
  121. Reiter, Robert E.; Witte, Owen N., PSCA: prostate stem cell antigen and uses thereof.
  122. Reiter,Robert E.; Witte,Owen N.; Saffran,Douglas C.; Jakobovits,Aya, PSCA: prostate stem cell antigen and uses thereof.
  123. Reiter,Robert E.; Witte,Owen N.; Saffran,Douglas C.; Jakobovits,Aya, PSCA: prostate stem cell antigen and uses thereof in pancreatic cancer.
  124. Gopal,T. Venkat, Peptide-mediated gene transfer.
  125. Mezo, Adam R.; McDonnell, Kevin A.; Hehir, Cristina A. Tan; Castro, Alfredo, Peptides that block the binding of IgG to FcRn.
  126. Mezo, Adam R.; McDonnell, Kevin A.; Hehir, Cristina A. Tan; Castro, Alfredo, Peptides that block the binding of IgG to FcRn.
  127. Barbara S. Slusher ; Paul F. Jackson ; Kevin L. Tays ; Keith M. Maclin, Pharmaceutical compositions and methods of effecting a neuronal activity in an animal using naaladase inhibitors.
  128. Barbara S. Slusher ; Rena Lapidus, Pharmaceutical compositions and methods of inhibiting angiogenesis using naaladase inhibitors.
  129. Slusher Barbara S. ; Jackson Paul F. ; Tays Kevin L. ; Maclin Keith M., Pharmaceutical compositions and methods of treating a glutamate abnormality and effecting a neuronal activity in an animal using NAALADase inhibitors.
  130. Jackson Paul F. ; Li Weixing ; Maclin Keith M. ; Tays Kevin L. ; Tsukamoto Takashi ; Slusher Barbara S., Phosphinic alkanoic acid derivatives.
  131. Jackson Paul F. ; Maclin Keith M. ; Tays Kevin L. ; Slusher Barbara S., Phosphonic acid derivatives.
  132. Jackson Paul F. ; Maclin Keith M. ; Tays Kevin L. ; Slusher Barbara S., Phosphonic acid derivatives.
  133. Sykes Thomas R.,CAX ; Woo Thomas K.,CAX ; Noujaim Antoine A.,CAX ; Qi Pei,CAX, Photoactivation of proteins for conjugation purposes.
  134. Hasan,Tayyaba; Savellano,Mark D.; Skobe,Mihaela, Photoimmunotherapies for cancer using combination therapies.
  135. Shekhani, Mohammed Saleh; Schatz, Robert W.; Pugh, Charles; Panasik, Jr., Nicholas; Stafford, Douglas, Polymyxin B conjugates.
  136. Queen Cary L. (Los Altos CA) Schneider William P. (Mountain View CA) Selick Harold E. (Belmont CA), Polynucleotides encoding improved humanized immunoglobulins.
  137. Griffiths Gary L. ; McBride William J., Position emission tomography using gallium-68 chelates.
  138. Meyer Damon L. ; Mallett Robert W., Pretargeting methods and compounds.
  139. Fritzberg Alan R. ; Abrams Paul G. ; Reno John M. ; Axworthy Donald B. ; Graves Scott S. ; Kasina Sudhakar, Pretargeting protocols for the enhanced localization of cytotoxins to target sites and cytotoxic combinations useful th.
  140. Carroll, Sean B., Prevention and treatment of sepsis.
  141. Paul F. Jackson ; Barbara S. Slusher, Prodrugs of NAALAdase inhibitors.
  142. Stagliano, Nancy E.; West, James W.; Kamath, Kathryn; Bessette, Paul H.; Sagert, Jason, Protease activatable interferon alpha proprotein.
  143. Mjalli, Adnan M. M.; Rothlein, Robert; Tian, Ye Edward; Webster, Jeffrey C.; Benjamin, Eric J., RAGE fusion proteins, formulations, and methods of use thereof.
  144. Mjalli, Adnan M. M.; Tian, Ye E.; Webster, Jeffrey C.; Rothlein, Robert, Rage fusion proteins.
  145. Mjalli, Adnan M. M.; Tian, Ye Edward; Webster, Jeffrey C.; Rothlein, Robert, Rage fusion proteins and methods of use.
  146. Niazi, Kayvan R.; Rabizadeh, Shahrooz; Bredesen, Dale E., Reagents and methods for cancer treatment and prevention.
  147. Niazi, Kayvan R.; Rabizadeh, Shahrooz; Bredesen, Dale E., Reagents and methods for cancer treatment and prevention.
  148. Waldman, Scott A., ST receptor binding compounds and methods of using the same.
  149. Afar, Daniel E.; Hubert, Rene S.; Raitano, Arthur B.; Saffran, Douglas C.; Mitchell, Stephen Chappell, Serpentine transmembrane antigens expressed in human cancers and uses therefor.
  150. Hubert, Rene S.; Raitano, Arthur B.; Saffran, Douglas; Afar, Daniel E. H.; Mitchell, Steven Chappell; Faris, Mary; Jakobovits, Aya, Serpentine transmembrane antigens expressed in human cancers and uses thereof.
  151. Stagliano, Nancy E.; West, James W.; Kamath, Kathryn; Bessette, Paul H.; Sagert, Jason G., Soluble notch receptor proproteins and methods of use thereof.
  152. Old, Lloyd J.; Ritter, Gerd; Jungbluth, Achim; Stockert, Elisabeth; Cavenee, Webster K., Specific binding proteins and uses thereof.
  153. Old, Lloyd J.; Ritter, Gerd; Jungbluth, Achim; Stockert, Elisabeth; Cavenee, Webster K., Specific binding proteins and uses thereof.
  154. Ritter, Gerd; Murray, Anne; Mark, George; Renner, Christoph, Specific binding proteins and uses thereof.
  155. Alt, Eckhard, Stent device and method.
  156. Goshorn,Stephen Charles; Graves,Scott Stoll; Schultz,Joanne Elaine; Lin,Yukang; Sanderson,James Allen; Reno,John M., Streptavidin expressed gene fusions and methods of use thereof.
  157. Virtanen, Jorma; Virtanen, Sinikka, Supramolecules containing binding and therapeutic molecules bound to hybridized nucleic acids.
  158. Orme, Jacob, System for selective cell treatment using ideotypically modulated pharmacoeffectors.
  159. Weinberg, Andrew D.; Vandenbark, Arthur A., T-cell antigens, and their use in diagnosis and treatment of T-cell mediated conditions.
  160. Reed Michael W. (Seattle WA), Targeting protein-diagnostic/therapeutic agent conjugates having Schiff base linkages.
  161. Kunz Lawrence L., Therapeutic inhibitor of vascular smooth muscle cells.
  162. Kunz Lawrence L., Therapeutic inhibitor of vascular smooth muscle cells.
  163. Kunz Lawrence L. ; Klein Richard A. ; Reno John M., Therapeutic inhibitor of vascular smooth muscle cells.
  164. Kunz Lawrence L. ; Klein Richard A. ; Reno John M. ; Grainger David J.,GB2 ; Metcalfe James C.,GB2 ; Weissberg Peter L.,GB2 ; Anderson Peter G., Therapeutic inhibitor of vascular smooth muscle cells.
  165. Kunz Lawrence L. ; Klein Richard A. ; Reno John M. ; Grainger David J.,GBX ; Metcalfe James C.,GBX ; Weissberg Peter L.,GBX ; Anderson Peter G., Therapeutic inhibitor of vascular smooth muscle cells.
  166. Kunz Lawrence L. ; Reno John M., Therapeutic inhibitor of vascular smooth muscle cells.
  167. Kunz, Lawrence L.; Anderson, Peter G., Therapeutic inhibitor of vascular smooth muscle cells.
  168. Kunz, Lawrence L.; Anderson, Peter G., Therapeutic inhibitor of vascular smooth muscle cells.
  169. Kunz, Lawrence L.; Anderson, Peter G., Therapeutic inhibitor of vascular smooth muscle cells.
  170. Kunz, Lawrence L.; Klein, Richard A., Therapeutic inhibitor of vascular smooth muscle cells.
  171. Kunz, Lawrence L.; Klein, Richard A., Therapeutic inhibitor of vascular smooth muscle cells.
  172. Kunz, Lawrence L.; Klein, Richard A.; Reno, John M., Therapeutic inhibitor of vascular smooth muscle cells.
  173. Kunz, Lawrence L.; Reno, John M., Therapeutic inhibitor of vascular smooth muscle cells.
  174. Kunz, Lawrence L.; Reno, John M., Therapeutic inhibitor of vascular smooth muscle cells.
  175. Lawrence L. Kunz ; John M. Reno, Therapeutic inhibitor of vascular smooth muscle cells.
  176. Lawrence L. Kunz ; Richard A. Klein ; John M. Reno, Therapeutic inhibitor of vascular smooth muscle cells.
  177. Jackson Paul F. ; Maclin Keith M. ; Wang Eric ; Slusher Barbara S. ; Lapidus Rena, Thio-substituted pentanedioic acid derivatives.
  178. Dees, H. Craig; Scott, Timothy C.; Smolik, John; Wachter, Eric A.; Fisher, Walter G., Topical medicaments and methods for photodynamic treatment of disease.
  179. Johns, Terrance Grant; Cavenee, Webster; Furnari, Frank; Scott, Andrew, Treatment method using EGFR antibodies and SRC inhibitors and related formulations.
  180. Weinberg Andrew D. ; Vandenbark Arthur A., Treatment of CD4 T-cell mediated conditions.
  181. Slusher Barbara S. ; Jackson Paul F., Treatment of global and focal ischemia using NAALADase inhibitors.
  182. Slusher Barbara S. ; Jackson Paul F., Treatment of global and focal ischemia using naaladase inhibitors.
  183. Slusher Barbara S. ; Jackson Paul F., Treatment of global and focal ischemia using naaladase inhibitors.
  184. Bayley Hagan ; Walker Barbara J. ; Chang Chung-yu ; Niblack Brett ; Panchal Rekha, Triggered pore-forming agents.
  185. Jeffrey J. Seilhamer ; Glenn Nedwin ; Tim Bringman ; Pierre-Oliver Couraud FR, Use of HL-60-related lectins in drug delivery and detection of lectin-expressing cells.
  186. Slusher Barbara S. ; Lapidus Rena S., Use of NAALADase activity to identify prostate cancer and benign prostatic hyperplasia.
  187. Wong, Kwok-Kin, Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease.
  188. Senger Donald R. (Medfield MA) Dvorak Harold F. (Newton MA), Vascular permeability factor targeted compounds.
  189. Kraus, Matthias H.; Aaronson, Stuart A., erbB-3 nucleic acids.
섹션별 컨텐츠 바로가기

AI-Helper ※ AI-Helper는 오픈소스 모델을 사용합니다.

AI-Helper 아이콘
AI-Helper
안녕하세요, AI-Helper입니다. 좌측 "선택된 텍스트"에서 텍스트를 선택하여 요약, 번역, 용어설명을 실행하세요.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.

선택된 텍스트

맨위로